161 related articles for article (PubMed ID: 37404767)
1. Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma.
Xu J; Chen C; Sun K; Shi Q; Wang B; Huang Y; Ren T; Tang X
Front Oncol; 2023; 13():1192472. PubMed ID: 37404767
[TBL] [Abstract][Full Text] [Related]
2. PI3K inhibitor impairs tumor progression and enhances sensitivity to anlotinib in anlotinib-resistant osteosarcoma.
Chen C; Guo Y; Huang Q; Wang B; Wang W; Niu J; Lou J; Xu J; Ren T; Huang Y; Guo W
Cancer Lett; 2022 Jun; 536():215660. PubMed ID: 35318116
[TBL] [Abstract][Full Text] [Related]
3. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells.
Liang L; Hui K; Hu C; Wen Y; Yang S; Zhu P; Wang L; Xia Y; Qiao Y; Sun W; Fei J; Chen T; Zhao F; Yang B; Jiang X
J Exp Clin Cancer Res; 2019 Feb; 38(1):71. PubMed ID: 30755242
[TBL] [Abstract][Full Text] [Related]
4. Anlotinib Reverses Multidrug Resistance (MDR) in Osteosarcoma by Inhibiting P-Glycoprotein (PGP1) Function In Vitro and In Vivo.
Wang G; Cao L; Jiang Y; Zhang T; Wang H; Wang Z; Xu J; Mao M; Hua Y; Cai Z; Ma X; Hu S; Zhou C
Front Pharmacol; 2021; 12():798837. PubMed ID: 35111065
[TBL] [Abstract][Full Text] [Related]
5. The function and mechanism of PSMD14 in promoting progression and resistance to anlotinib in osteosarcoma.
Liu Z; Wang X; Li C; Zhao R
Cancer Cell Int; 2023 Dec; 23(1):309. PubMed ID: 38053170
[TBL] [Abstract][Full Text] [Related]
6. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.
Wang G; Sun M; Jiang Y; Zhang T; Sun W; Wang H; Yin F; Wang Z; Sang W; Xu J; Mao M; Zuo D; Zhou Z; Wang C; Fu Z; Wang Z; Duan Z; Hua Y; Cai Z
Int J Cancer; 2019 Aug; 145(4):979-993. PubMed ID: 30719715
[TBL] [Abstract][Full Text] [Related]
7. Anlotinib inhibits the progress of colorectal cancer cells by antagonizing VEGFR/JAK2/STAT3 axis.
Jia ZX; Zhang Z; Li Z; Li A; Xie YN; Wu HJ; Yang ZB; Zhang HM; Zhang XM
Eur Rev Med Pharmacol Sci; 2021 Mar; 25(5):2331-2343. PubMed ID: 33755971
[TBL] [Abstract][Full Text] [Related]
8. Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC.
Wang S; Lou N; Luo R; Hao X; Liu Y; Wang L; Shi Y; Han X
J Transl Med; 2022 May; 20(1):248. PubMed ID: 35642002
[TBL] [Abstract][Full Text] [Related]
9. Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway.
Xu P; Wang H; Pan H; Chen J; Deng C
Cancer Chemother Pharmacol; 2022 Feb; 89(2):183-196. PubMed ID: 34997858
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumour effect of tocilizumab for osteosarcoma cell lines.
Hagi T; Nakamura T; Kita K; Iino T; Asanuma K; Sudo A
Bone Joint Res; 2020 Nov; 9(11):821-826. PubMed ID: 33179539
[TBL] [Abstract][Full Text] [Related]
11. Low‑dose anlotinib combined with EGFR‑TKI can be used as an alternative for EGFR‑TKI‑resistant non‑small cell lung cancer in elderly patients.
Chen Y; Jiang N; Liang X; Chen N; Chen Y; Zhang C; Shi J; Guo R
Oncol Lett; 2023 Aug; 26(2):323. PubMed ID: 37415629
[TBL] [Abstract][Full Text] [Related]
12. TGF-β Signaling Activation Confers Anlotinib Resistance in Gastric Cancer.
Chen J; Hai Y; Hu Q; Chen C; Jiang X; Gao Y
Pharm Res; 2023 Mar; 40(3):689-699. PubMed ID: 36539669
[TBL] [Abstract][Full Text] [Related]
13. Effective treatment of anlotinib in giant delayed pulmonary metastasis of osteosarcoma: a case report and literature review.
Long ZY; Lu Y; Li M; Chen G; Shi L; Xiao X; Bai Y; Zhang HM; Wang Z
Ann Palliat Med; 2021 Jun; 10(6):7073-7082. PubMed ID: 33548989
[TBL] [Abstract][Full Text] [Related]
14. Anlotinib Exerts Inhibitory Effects against Cisplatin-Resistant Ovarian Cancer In Vitro and In Vivo.
Ji Y; Li X; Qi Y; Zhao J; Zhang W; Qu P
Molecules; 2022 Dec; 27(24):. PubMed ID: 36558006
[TBL] [Abstract][Full Text] [Related]
15. Attenuation of STAT3 Phosphorylation Promotes Apoptosis and Chemosensitivity in Human Osteosarcoma Induced by Raddeanin A.
Wang Z; Wang C; Zuo D; Zhang T; Yin F; Zhou Z; Wang H; Xu J; Mao M; Wang G; Hua Y; Sun W; Cai Z
Int J Biol Sci; 2019; 15(3):668-679. PubMed ID: 30745853
[TBL] [Abstract][Full Text] [Related]
16. IL-6 Promotes Cancer Stemness and Oncogenicity in U2OS and MG-63 Osteosarcoma Cells by Upregulating the OPN-STAT3 Pathway.
Zhang C; Ma K; Li WY
J Cancer; 2019; 10(26):6511-6525. PubMed ID: 31777581
[No Abstract] [Full Text] [Related]
17. Anlotinib Exerts Anti-Cancer Effects on KRAS-Mutated Lung Cancer Cell Through Suppressing the MEK/ERK Pathway.
Hu H; Liu Y; Tan S; Xie XX; He J; Luo F; Wang L
Cancer Manag Res; 2020; 12():3579-3587. PubMed ID: 32547195
[TBL] [Abstract][Full Text] [Related]
18. miRNA-221-3p derived from M2-polarized tumor-associated macrophage exosomes aggravates the growth and metastasis of osteosarcoma through SOCS3/JAK2/STAT3 axis.
Liu W; Long Q; Zhang W; Zeng D; Hu B; Liu S; Chen L
Aging (Albany NY); 2021 Aug; 13(15):19760-19775. PubMed ID: 34388111
[TBL] [Abstract][Full Text] [Related]
19. Radiotherapy opens the blood-brain barrier and synergizes with anlotinib in treating glioblastoma.
Li PJ; Lai SZ; Jin T; Ying HJ; Chen YM; Zhang P; Hang QQ; Deng H; Wang L; Feng JG; Chen XZ; Guo P; Chen M; Tian Y; Chen YY
Radiother Oncol; 2023 Jun; 183():109633. PubMed ID: 36963438
[TBL] [Abstract][Full Text] [Related]
20. Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab.
Liu Z; Qin T; Yuan X; Yang J; Shi W; Zhang X; Jia Y; Liu S; Wang J; Li K
Front Oncol; 2022; 12():875888. PubMed ID: 35664796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
